cmi_logo.png
[Latest] Global Patient Simulator Market Size/Share Worth USD 1,421.5 Million by 2032 at a 8.9% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
August 01, 2023 12:30 ET | Custom Market Insights
Austin, TX, USA, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Patient Simulator Market Size, Trends and Insights By Product Type (Adult...
SimpliFed Announces Improved Baby Formula Access Through Transparency and Evidence-Based Research: First-ever baby feeding company to offer both breastfeeding and baby formula support, with on-demand, data-driven, judgment-free baby feeding experts
SimpliFed Announces Improved Baby Formula Access Through Transparency and Evidence-Based Research
March 01, 2023 04:00 ET | SimpliFed
ITHACA, NEW YORK, March 01, 2023 (GLOBE NEWSWIRE) -- SimpliFed, the telehealth service dedicated to democratizing access to inclusive infant feeding support, announced that it has launched a...
Official advertisement example for SimpliFed and Aetna announcement. SimpliFed Expands Into Commercial Provider Networks; Virtual Support Prepares Working Parents for Positive Baby Feeding Experience
SimpliFed Expands Into Commercial Provider Networks
January 31, 2023 04:00 ET | SimpliFed
ITHACA, NY, Jan. 31, 2023 (GLOBE NEWSWIRE) -- SimpliFed, the telehealth platform dedicated to infant nutrition and parental support, announced today that in addition to serving TRICARE...
GMILogo_Vertical-Gradient.png
Extracorporeal Membrane Oxygenation Market to hit USD 639 Million by 2032, says Global Market Insights Inc.
December 12, 2022 06:10 ET | Global Market Insights Inc.
Selbyville, Delaware, Dec. 12, 2022 (GLOBE NEWSWIRE) -- The extracorporeal membrane oxygenation market value is set to reach USD 639 million by 2032, according to a new research report by Global...
nfant Announces New Thrive Feeding System and Partnerships with SimpliFed and bttn
nfant Announces New Thrive Feeding System and Partnerships with SimpliFed and bttn, at HLTH 2022
November 14, 2022 07:00 ET | nfant
LAS VEGAS, NEVADA, Nov. 14, 2022 (GLOBE NEWSWIRE) -- nfant® today unveiled the nfant Thrive Feeding System, its parent-focused connected home nursery product line that applies cutting-edge...
SimpliFed, the maternal telehealth platform dedicated to infant nutrition and parental support, announced that the company’s virtual baby feeding services are now available to all Health First Colorado beneficiaries.
SimpliFed to Provide Virtual Baby Feeding Support Services to Health First Colorado Beneficiaries
August 17, 2022 04:00 ET | SimpliFed
ITHACA, NY, Aug. 17, 2022 (GLOBE NEWSWIRE) -- SimpliFed, the maternal telehealth platform dedicated to infant nutrition and parental support, announced that the company’s virtual baby feeding...
Medela and Expectful Strengthening Support For New Mothers
Medela and Expectful Partner to Strengthen Support for New Mothers
May 05, 2022 08:00 ET | Medela
McHenry, IL, May 05, 2022 (GLOBE NEWSWIRE) -- Medela, the most trusted breast pump brand*, has announced a partnership with Expectful, a holistic maternal health platform for fertility, pregnancy,...
logo.PNG
爱科百发宣布爱司韦™在治疗呼吸道合胞病毒(RSV)感染的住院婴幼儿中的临床三期试验达到主要终点
April 07, 2022 03:50 ET | Shanghai Ark Biopharmaceutical Co., Ltd.
在临床三期AirFLO试验中,爱司韦™与安慰剂相比显著降低症状评分(p=0.002)及病毒载量(p=0.006),达到试验主要终点和关键次要终点 RSV感染是五岁以下儿童因病毒感染而住院及死亡的首要因素爱司韦™是全球首个成功在儿童患者人群中完成关键性三期临床研究的RSV抗病毒药物爱司韦™计划于2022年年中向中国监管机构提交新药上市申请 上海, April 07, 2022 (GLOBE...
logo.PNG
愛科百發宣佈愛司韋™在治療呼吸道合胞病毒(RSV)感染的住院嬰幼兒中的臨床三期試驗達到主要終點
April 07, 2022 03:50 ET | Shanghai Ark Biopharmaceutical Co., Ltd.
在臨床三期AirFLO試驗中,愛司韋™與安慰劑相比顯著降低症狀評分(p=0.002)及病毒載量(p=0.006),達到試驗主要終點和關鍵次要終點 RSV感染是五歲以下兒童因病毒感染而住院及死亡的首要因素愛司韋™是全球首個成功在兒童患者人群中完成關鍵性三期臨床研究的RSV抗病毒藥物愛司韋™計畫於2022年年中向中國監管機構提交新藥上市申請 上海, April 07, 2022 ...
logo.PNG
ArkBio Announces Positive Results of Phase 3 Study with Ziresovir in Infants and Children Hospitalized with Respiratory Syncytial Virus Infection
April 07, 2022 03:50 ET | Shanghai Ark Biopharmaceutical Co., Ltd.
Phase 3 AirFLO study with ziresovir met primary and key secondary endpoints of significant reduction of sign-and-symptom score (p=0.002) and viral load (p=0.006) respectively, compared with...